Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Karuna Therapeutics Inc.

www.karunatx.com

Latest From Karuna Therapeutics Inc.

IPO Update: 28 Biopharma Companies Raise $3bn, Provide An Average 10% Return

Even though half of the drug developers that have gone public in the US during the first two quarters of the year are providing negative returns, the 13 companies trading in positive territory bring the class of 2019's average return to 10%.

Financing Business Strategies

Finance Watch: Investors Bet On Hope As Four Early-Stage Companies Launch US IPOs

Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.

Financing Business Strategies

Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies

The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.

Financing StartUps and SMEs

IPO Update: Pace Of US Offerings Slows As 13 Biopharmas Go Public In 2019

With about three IPOs per month compared with a pace of nearly six per month in 2018, drug developers have raised $1.55bn with US offerings this year – though returns have been mixed.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Karuna Therapeutics Inc.
  • Senior Management
  • Steven Paul, MD, CEO
    Troy Ignelzi, CFO
    Andrew Miller, PhD, COO
    Stephen Brannan , MD, CMO
  • Contact Info
  • Karuna Therapeutics Inc.
    Phone: (857) 449-2244
    33 Arch St.
    Ste. 3110
    Boston, MA 02110
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register